Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **pelvic floor musculature** refers collectively to the group of skeletal muscles and associated connective tissue forming the base of the pelvic cavity in both men and women[1][2][3][4][5][7]. The primary components are the **levator ani** muscles—subdivided into pubococcygeus, puborectalis, and iliococcygeus—and the **coccygeus (ischiococcygeus) muscle**[1][4][5]. These muscles support the pelvic organs (bladder, uterus/prostate, and rectum), maintain urinary and fecal continence, facilitate childbirth, and contribute to sexual function[1][2][3][5][7]. They are innervated mainly by branches of the pudendal nerve (S2–S4) and other sacral nerves[1][4][5]. Dysfunction or weakening of this musculature can result in disorders such as pelvic organ prolapse, various forms of incontinence, and sexual disorders[3][4][7]. The pelvic floor is not a single molecular or receptor-based therapeutic target, but rather an anatomical and functional muscle group, which is why it is not generally regarded as a traditional "therapeutic target" in molecular medicine. **Note:** - This entry is marked as *is_incorrect: true* because "pelvic floor musculature" is an anatomical muscle group rather than a molecular target, receptor, enzyme, transporter, or other entity typically considered a direct therapeutic target in pharmacology or molecular medicine. No drugs directly target the pelvic floor musculature at the molecular level, although interventions such as physical therapy or, in some cases, neuromodulation may affect its function[4][7]. - No canonical abbreviation or molecular aliases exist, and the "molecular classification" is best described as "Other" (anatomical, not molecular). - Drugs do not interact with the pelvic floor musculature as a unique molecular entity, so mechanisms specific to a receptor or enzyme do not apply. - No specific biomarkers or direct safety concerns (in clinical drug development sense) are identified beyond general issues related to muscle injury or dysfunction.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pelvic floor musculature.